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ÖzAbstract
Near-IR (NIR) (yakın kızıl ötesi) floresan boyalarla hedefe yönelik görüntüle-
me (tanı) ve tedavi imkânı, görüntülerin renk yansıması ve floresan emisyo-
nundan alınan datalar yardımıyla gerçekleştirilir ve özellikle derin yüzeyde 
bulunan dokuların görüntülenmesinde önemli rol oynar. Bu moleküllerin so-
ğurma ve floresans yaptıkları bölge NIR spektroskopisinin (NIRS) moleküler 
görüntülemelerdeki seçici alanı olarak tanımlanır (650-850 nm). NIR floresan 
boyalar genel olarak NIR görüntüleme içeren çalışmalarda kullanılmasına 
rağmen günümüzde fotodinamik tedavi de kendine yer bulmaktadırlar. Kli-
nik öncesi araştırmalarda, ftalosiyanin, klorin, porfirin, bakterioklorin, siyanin, 
alexfluore ve çeşitli bodipy serileri vb. NIR floresan boyalar/ajanlar kullanıl-
maktadır. Bu boyalardan özellikle görüntüleme çalışmalarında en öne çıkanı, 
diğer boyalara kıyasla ileri fotofiziksel ve kimyasal özelliklere sahip ftalosiya-
ninlerdir. NIR boyaların kullanılmasının mevcut ve potansiyel avantajlarının 
yanında bu boyaların toksisite sorunu boyaların klinikte kullanılmasını kısıt-
lamaktadır. Klinikte kullanılan FDA onaylı tek boya indosiyanin yeşilidir ve 
ihmal edilebilir yan etkileriyle, kardiyak fonksiyonların kontrolü, karaciğer çık-
tıları ve retinal anjiyografi gibi klinik alanlarda kullanılmaktadır. Sonuç olarak, 
birçok önemli sorunlar taşımakla birlikte günümüzde hala güvenli kullanıma 
uygun olmayan NIR boyaların yakın gelecekte bahsi geçen uygulamalarda 
uygun olarak kullanılabilecek kimyasal, fotokimyasal ve fotofiziksel özellikleri 
geliştirilmiş şekilde üretilmesi ihtiyacı kaçınılmazdır. Bununla beraber gelişti-
rilmiş ve/veya geliştirilecek olan NIR floroforların nanopartiküler sistemlerle 
birleştirilerek ve/veya ajan moleküller ile hedef belirlenerek NIRS ve terapi 
yönünden daha avantajlı hale getirilmesi gereklidir.
Anahtar Kelimeler: Yakın kızıl ötesi boyalar, fotodinamik terapi, ftalosiya-
nin, teranostik, hedefe yönelik görüntüleme, floresan sistemler
INTRODUCTION
Near-IR (NIR) Dyes
Fluorescence-based detection provides support to a number of biological assays including but not limited to immunoassays, flow cy-
tometer, DNA sequencing, various proteomics assays, and several clinical chemistry applications. Because of recent advances in the 
field, the efficiency of these assays has to be amplified.  In recent years, when minimal background fluorescence and low scattering in 
the 650–850 nm region of the electromagnetic spectrum (Figure 1) were coupled with photophysically and chemically improved fluoro-
phores, near-infrared (NIR) dye-based fluorescence imaging gained importance (1, 2). Although the primary purpose of the NIR dyes is 
aiding imaging, some of the NIR dyes are also used as therapeutic agents for photodynamic therapy (PDT) of cancer and other diseases. 
NIR dyes show variety based on their solubility, molar absorptivity, photostability, and fluorescence efficiency. Phthalocyanines (Pcs), cy-
anines, BODIPY dye series porphyrins, squarins, benzo [c] heterocyclic, and xanthine derivatives are the most commonly used NIR dyes 
(3-5). Among these dyes, cyanine dyes receive attention because of their high molar absorptivity, strong fluorescence emission, and good 
photostability. However, their excitation and emission spectra interference as a result of intrinsic small stokes shift  is an obstacle for their use 
as NIR imaging agents (6). Porphyrins are tetrapyrolic compounds. Depending on the substituent pattern on the macrocycle, their chemical 
Targeted imaging (diagnosis) and therapy using near-infrared (NIR) dyes 
can be accomplished with the help of the data obtained from fluorescence 
emission of the fluorophores and play an important role particularly in 
deep tissue imaging. The area NIR dyes absorb and emit light is defined as 
NIR spectroscopy (NIRS, 650–850 nm). Although NIR dyes are widely used 
for imagining purposes, they also find application in photodynamic ther-
apy. In preclinical studies, phthalocyanine (Pc), chlorine, porphyrin, bac-
teriochlorin, cyanine, Alexa-fluor, and various BODIPY dye series are used 
as NIR fluorescent dyes/agents. When compared to other dyes, one of the 
most promising NIR dye is Pc because of their photophysical and chemi-
cal properties particularly for the imaging applications. Although NIR dyes 
have several advantages, their toxicity limits their usage in clinics. Indocy-
anine green, having negligible side effects, is the only FDA approved NIR 
dye used in clinics. It is used for controlling of cardiac function, liver output, 
and retinal angiography. In conclusion, the development of new genera-
tion NIR dyes with improved chemical, photophysical, and photochemical 
properties that are more appropriate for the aforementioned applications 
is inevitable. Nevertheless, the NIR dyes that have been developed and will 
be developed should be combined with the nanoparticular systems and/or 
targeting moieties to make them more advantageous for NIRS and therapy. 
Keywords: Near-infrared dyes, photodynamic therapy, phthalocyanine, 
theranostic, targeted imaging, fluorescent probes
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and photochemical properties can be easily tuned. Instead of being 
used as NIR imaging dyes, porphyrins are predominantly used for PDT 
applications because of their ability to form triplet state complexes via 
intersystem crossing and to generate reactive oxygen species. A deriv-
ative of porphyrin, chlorin, is a two electron reduced from of porphyrin 
and is widely used as a photosensitizer (PS) for PDT applications, which 
will be further elaborated in the following sections of this review. 
Compared to porphyrin derivatives and cyanines, BODIPY series have 
lower molecular weight (Figure 2) and last within the cells for a lon-
ger period of time, which provides a better time scale for imaging. 
BODIPY dyes have many derivatives having absorption and emis-
sion profile ranging from 500 nm to 660 nm in the electromagnetic 
spectrum (Figure 3). However, typically they have a relatively short-
er wavelength emission maxima and smaller extinction coefficients 
compared to the other NIR-active fluorophores (e.g., Pcs) (7, 8).
Pcs, known systematically as tetraaza tetra benz porphyrins, are a 
member of porphyrinoid derivative aromatic compounds (Figure 4). 
Pcs are planar macrocycles with 18 p electrons. In the Pc structure, aza 
bridges connect four isoindole units linked together through their 1, 
3 positions (Figure 4). Pcs have a number of characteristic proper-
ties such as high thermal stability, unique photophysical properties, 
intense color, non-toxicity, and high phototoxicity upon irradiation 
with light, contributing to their effectiveness in different research 
areas. Their easily tunable photochemical and photophysical prop-
erties such as narrow absorbance and emission band and resistance 
to photobleaching, by changing the substitution pattern around the 
Pc aromatic core and/or the central metal atom, makes these com-
pounds highly appropriate for applications such as PCR, single gene 
mutation detection, and resonance energy transfer-based assays (9).
CLINICAL AND RESEARH CONSEQUENCES 
For most of the applications, it is a “must” to have Pcs with high wa-
ter solubility along with a functional group that can be used for bio-
conjugation. However, difficulties in their synthesis limit their usage; 
therefore, a new synthetic method has been developed by Erdem et 
al. (1, 2) that has been published in two different articles in 2008 and 
2009 in the Journal of Organic Chemistry Article (1, 2). In these stud-
ies, using a new solid phase synthesis method, Erdem et al. (2) were 
able to synthesize monoamine and mono-hydroxyl functionalized 
highly water-soluble Pcs to be used as NIR imaging agents. Further 
expansion of the study included the conjugation of monoamine 
functionalized Pcs to various length oligonucleotides. The authors 
successfully showed that the synthesis and isolation of the Pc–oligo-
nucleotide conjugate takes just few hours with the help of a three-
step specific bioconjugation method. 
For many bioanalytical applications, Pcs are used as fluorophores 
to tag biomolecules because of their structural properties. They are 
specifically useful fluorescence on-off systems offering high target to 
background ratio due to Pcs high extinction coefficients and strong 
and narrow emission profiles. In the light of this information, Nest-
erova et al. (9) have published another article in the Journal of Amer-
ican Chemical Society in 2009 as a follow up study (9). In this study, 
authors, for the first time, have designed, prepared, and evaluated 
the use of double-labeled dimerization-based molecular beacons 
Figure 2. General structure of BODIPY dyes (6)
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Figure 3. Normalized fluorescence emission spectra of BODIPY series
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Figure 4. General structure of porphyrin and chlorin
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using Pcs as markers for single nucleotide base pair detection to be 
used in vivo cell imaging to trace cancer cells. For this purpose, the 
authors have designed “off/on probe” in a way that two identical Pc 
molecules in the molecular beacon’s closed state form a non-fluo-
rescent H-dimer (off state). However, in the presence of a comple-
mentary DNA, the molecular beacon’s loop hybridizes to its target 
forcing the molecular beacons to open, disrupting the Pc dimer and 
restoring fluorescence emission (on state) (Figure 5) (9). On the other 
hand, in the presence of a single base-pair mismatch, the loop does 
not open due to mismatch between the loop and the complimentary 
DNA, the probe stays in the off state and consequently fluorescence 
read-out does not get recorded. 
A different perspective of Pc aggregation-based system (on/off 
probe) has been described in another study published in the Analyst 
in 2010. Nesterova et al.  (10) developed a Pc aggregation-based NIR 
fluorescence quenching system employing only one type of a fluo-
rophore. With the aim of discovering inhibitors for long interspersed 
Element 1 endonuclease, the authors successfully demonstrated 
that the probe could effectively distinguish differences in enzyme 
activity via H-aggregation of single Pc-labeled oligonucleotide.  The 
probe designed in a way that Pc bearing oligonucleotide is used as 
a fluorescence quenching system. In the generated probe-based 
system, in the absence of the enzyme, two fluorophores are located 
far away from each other (on the either end of the double strand-
ed oligonucleotide) so that the fluorescence read out is recorded 
(on state). As the enzyme is introduced in the system, it cleaves the 
double stranded oligonucleotide. Consequently, fluorophores (Pc) 
get close to each other in the solution resulting in quenched fluores-
cence (off state) (Figure 6). The advantage of using only one type of 
a fluorophore is reduced cost and time for substrate preparation. The 
signal read-out format overcomes some disadvantages of the “off/on 
system.” In the signal read-out format, amplification of the signal is 
monitored against a low background (10).  It is concluded that such 
a system would be particularly beneficial in high throughput screen-
ing applications, in which enzyme activity is closely monitored.
Besides on/off or off/on systems, NIR imaging can be coupled with 
nanoparticles to increase detection efficacy by measuring the num-
ber of fluorophores in the tissue of interest. Nanoparticles have many 
advantages such as tunable pharmacokinetics, increased number of 
fluorophores per area, and the ability to carry more than one type of a 
molecule (therapeutic, diagnostic, and biomarker targeted). All these 
features make nanoparticles an attractive choice as drug carriers for 
theranostic studies in recent years (in vivo and in vitro). McCarthy et 
al. (11) study of thrombus targeted fibrinolytic nanoparticles is one 
of the best examples in the nanoparticles’ usage in NIR imaging (11).
Thrombus, blood clot, is the final product of the blood coagulation 
step in hemostasis and is formed by aggregated platelets and a mesh 
of cross-linked fibrin protein (12-15). Although currents effective-
ly lyse clots and prevent tissue and organ death using exogenous 
plasminogen activators (PAs), these PAs may also damage normal 
hemostasis, which may lead to life-threatening bleeding such as in-
tra-cerebral hemorrhage. McCarthy et al. (16) aimed to develop new 
thrombus-targeted fibrinolytic agents that employ the multifunc-
tional theranostic nanomaterial to generate efficacious thrombolytic 
effects, while minimizing deleterious side effects (16). In this study, 
the authors developed thrombus targeting theranostic nanoparti-
cles using cross-linked dextran coated iron-oxide (FeO) nanoparticles 
carrying imaging, therapeutic, and targeting agents. The surface of 
the FeO nanoparticles were functionalized with free amine groups 
so that imaging and targeting agents with amine reactive functional 
groups can be covalently attached to the surface of the nanoparticle. 
To accomplish thrombus targeting, the nanoparticle was decorat-
ed with an activated factor XIII (FXIIIa)-sensitive peptide. Therapeu-
tic ability is provided using tPA, which is covalently conjugated to 
nanoparticles via PEG linker (Figure 7). Commercially available car-
boxylic acid bearing VT680 dye is used as florescence reporter (16).
Following the synthesis of nanoparticles, the applicability of the FXII-
Ia-targeted thrombolytic nanoagent in the treatment of thromboem-
bolism was demonstrated in vitro and in vivo in a murine model of 
arterial and venous thrombosis. Investigation of the safety profile of 
the nanoagent was planned to performed in another study (16).
Although it is beneficial to use fluorescence imaging, NIR imaging 
can be coupled with other imaging technologies such as magnetic 
resonance imaging and optical coherence tomography (OCT) to im-
prove detection/imaging efficiency. In one of the most recent papers 
published in European Heart Journal in 2015 by Hara et al. (16), the 
dual imaging (NIRF-OCT) system for intravascular fibrin after stent 
implantation, which has a potentially clinically translatable technolo-
gy, has been studied. In this study, the authors reported about diag-
Figure 5. Dimerization-based molecular beacons assay using Pc dyes (9)
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nosis and prevention of stent thrombosis, which is a life-threatening 
complication of coronary artery stent implantation that occurs when 
a blood clot forms acutely within a stent in both bare metal stents 
(BMS) and drug-eluting stents (DES). OCT is a non-invasive imaging 
test that uses light waves to take cross-section pictures of your reti-
na and is increasingly used for assessing stent tissue coverage as a 
measure of healed stents (17-21). Although OCT is increasingly used 
for assessing stent tissue coverage as a measure of healed stents, it 
cannot accurately identify whether an overlying tissue represents 
physiological neointima. In this study, the authors evaluated and 
compared fibrin deposition and persistence on BMS and DES using 
NIRF molecular imaging in vivo, in combination with simultaneous 
OCT (22).
The identification of overlying tissue represents physiological neoin-
tima visualized by near-infrared fluorescence (NIRF) molecular imag-
ing in vivo, in combination with simultaneous OCT stent coverage 
(23, 24). The authors employed CyAm7 as an NIR reporter dye. Fi-
brin targeted imaging agent consisting of a fibrin targeting peptide 
and CyAm7 was prepared and validated in murine thrombosis. For 
in vivo studies, rabbits underwent an implantation of one BMS and 
DES without overlap. At Days 7 and 28, intravascular NIRF-OCT was 
performed following the injection of fibrin-targeted NIRF molecu-
lar imaging agent FTP11-CyAm7. Compared with BMS, DES showed 
greater fibrin deposition and fibrin persistence at Days 7 and 28. The 
results showed that the detection efficiency of unhealed stents is 
improved by intravascular NIRF fibrin molecular imaging techniques. 
A significant percentage of stents evaluated using OCT are found to 
be covered by fibrin, specifically in DES. Thus, there is a great possi-
bility that such stents might remain prothrombotic. These findings 
indicate the specificity of clinical OCT for the evaluation and follow 
up of stent healing.
In another thrombosis-based study, Stein-Merlob et al. (22) NIR im-
aging is coupled with different imaging technologies. In this study, 
published in 2015 in the authors utilized high-resolution in vivo op-
tical molecular imaging with FTP11, a NIRF fibrin-specific reporter, to 
investigate the in vivo inter relationships of blood accessibility to fi-
brin, thrombus age, thrombus neoendothelialization, and fibrinolysis 
in murine venous thrombosis (VT). Theranostic IVM fibrin molecular 
imaging strategy was developed to predict the fibrinolytic response 
based on fibrin accessibility of FTP11via imaging signal. NIRF micros-
copy showed that FTP11 fibrin binding was thrombus age-depen-
dent. FTP11 localized to the luminal surface of early-stage VT, but 
only minimally to subacute VT. The authors concluded that VT fibri-
nolysis diminishes with thrombus age and relates to the accessibility 
of fibrin to blood-based fibrinolytic enzymes. Also the in vivo FTP11 
fibrin accessibility signal predicts the efficacy of exogenous fibrino-
lysis (25).
Fibrin is the major proteinaceous component of the initial thrombus 
scaffold and provides a surface for thrombus propagation and even-
tual vessel occlusion.
As discussed above, current imaging techniques provide accurate in-
formation about the presence of thrombus and the blood flow within 
the vessel. However, important aspects, such as the age and anato-
my, of the thrombus cannot be detected using the present method-
ologies. Therefore, new techniques, having huge potential, are being 
explored (25).
NIR dyes are valuable not only for imaging but also for the detec-
tion of enzyme activity (26-29). Konishi et al. (30) have published 
one recent example of this in 2015 in Circulation Journal. The au-
thors proved that NIR imaging can be also used for the detection of 
enzymatic activity. This study validates a novel molecular imaging 
tool that enables the in vivo visualization of granzyme B activity, a 
major effector of cytotoxic CD8+ T lymphocytes. The authors syn-
thesized and optimized a fluorogenic substrate capable of reporting 
on granzyme B activity. The substrate composed of polylysine graft 
copolymer and granzyme B specific peptide. The peptide having the 
sequence GIEFDSGGC is modified with Cy5.5-analogous (CyAl5.5B) 
fluorescent dye on the N terminus (Figure 8). The probe’s specifici-
ty examined ex vivo in mice hearts with experimental cytotoxic 
CD8+-mediated myocarditis using fluorescence reflectance imaging. 
Granzyme B, released from CD8+ T cells, induces apoptotic death of 
target cells by caspase-dependent mechanisms, and a major effector 
of cytotoxic CD8+ T is lymphocytes. In the continuation of the study, 
in vivo experiments were carried for the detection of localized gran-
zyme B activity in murine model with acute myocarditis. Fluorescent 
molecular tomography in conjunction with co-registered computed 
tomography imaging was employed for in imaging purposes. The 
authors confirmed that molecular imaging of granzyme B activity 
can visualize T cell-mediated myocardial injury and monitor the re-
sponse to an anti-inflammatory intervention. Although for clinical 
translation there are still limitations such as the depth dependence 
of fluorescence imaging that prevents this method to be used on 
large animal or human hearts, this will be a pilot study for the future 
development of further novel tools that can investigate the mech-
anisms of immune-mediated cardiac processes, including acute 
cardiac transplant rejection, and evaluate the effects of therapeutic 
interventions (30).
A recent study published in the Journal of Biomedical Optics by Er-
dem et al. (31) in 2014 is another example of the detection of en-
zymatic activity using fluorescence as a tool (31). Authors designed 
and synthesized a β-lactam specific probe (off/on probe) to be able 
to detect one of the most commonly prescribed antibiotic β-lact-
am’s antibiotic susceptibility and resistance in less than 30 min. For 
this purpose, β-lactam core of the antibiotic was modified with two 
identical BODIPY dyes to serve as fluorophores. When the enzyme is 
not introduced, two fluorophore are in close proximity and quench 
each other’s fluorescence (off state). When the β-lactamase enzyme 
is introduced to the system, the β-lactam core is cleaved and fluoro-
Figure 8. Modification of the polylysine graft copolymer and 
fluorescence activation (30)
CGGSDFEIG
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DFEIG
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phores are separated and get way from each other. Consequently, 
the system gains fluorescence (on state) and fluorophores dequench. 
According to the quenching-dequenching, antibiotic resistance of an 
individual can be clarified in an easy and quick way (Figure 9).  
Therapy
Besides their usage in various imaging platforms, some of the NIR im-
aging agents are also used as a PS in PDT applications (32-35). PDT is 
a promising non-invasive localized treatment modality for a diverse 
range of diseases, including various types of cancers, infections, and 
inflammatory conditions. It involves combination of light and a PS. PS 
is activated after treatment with light, and it causes local tissue dam-
age via the generation of reactive oxygen species (ROS) (Figure 10). 
PSs that are being used in PDT are usually highly hydrophobic mole-
cules with very low water solubility. As a result of low solubility, these 
molecules tend to aggregate and cause reduced ROS generation. The 
aforementioned cascade of events causes low PDT efficiency. Some 
of the PSs’ general structures are shown in Figure 11 (36, 37).
In a recent review paper published by Avcı et al. (37) the overall goal 
of PDT is described as destroying the target tissue, while leaving 
healthy tissues undamaged. However, while target tissues take up 
PS with some selectivity, some PS also accumulates in surrounding 
healthy tissues. Thus, another limiting factor of PDT is that light di-
rected at the targeted tissue site may damage adjacent healthy tis-
sues. This prevents the use of higher PS amounts, which potential-
ly leads to incomplete treatment responses. To solve this problem, 
many laboratories have been working on the development of new 
methods for site-specific delivery of PS such as the encapsulation of 
PS into drug delivery vehicles (37).
The authors also elaborated the PSs’ self-assembly to form nanopar-
ticles for PDT. To improve PS delivery to the specific site, they are of-
ten encapsulated or conjugated in/on nano-drug delivery vehicles 
including but not limited to liposomes, fullerosomes, and nanocells. 
Taken together, based on their conclusion, PDT-based activation 
incorporated with nanotechnology can further enhance effective 
drug-delivery while minimizing side-effects and is expected to be 
clinically applicable in the near future.
Last but not the least, in 2014, another article has been published 
by Spring et al. (38) to show that it is possible to selectively treat mi-
croscopic tumors using an activatable immunoconjugate utilizing 
a NIR dye (38). The team chose to treat micro metastases because 
in standard therapies, they are not detected until the late stage of 
the disease. The detection is proceeded by immunoconjugate com-
posed of self-quenching, near infrared chromophores loaded onto a 
cancer cell-targeting antibody. In the mentioned study, EGFR mono-
clonal antibody (mAb) was used as to target cancer cells overex-
pressing EGFR. EGFR is an important molecule for targeting cancer 
cells that displays elevated expression in up to 70% of EOCs and in 
many other carcinomas (39, 40). Benzoporphyrin derivative is a clin-
ically-approved NIR photoactivable and cytotoxic chromophore. 
After conjugation with an antibody it undergoes electronic excited 
singlet state quenching and although fluorescence is activated as a 
result of lysosomal proteolysis, chromophore phototoxicity is gained 
after light treatment following cancer cell internalization enabling 
tumor-confined photocytotoxicity and the resolution of individual 
micrometastases. Although EGFR-targeting is the focus here, immu-
Figure 9. On/off state scheme of β-lactamase enzyme-activated 
fluorophore (β-LEAF) (31)
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Figure 11. General structures of photosensitizers (6)
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noconjugate synthesis, imaging, and taPIT can be applied to many 
other targets. This unique antibody-based system that couple both 
NIR imaging and PDT in the same platform does not only introduce 
a therapeutic strategy to help destroy residual drug-resistant cells 
but also provides a sensitive imaging method to monitor micromet-
astatic disease in common sites of recurrence and provides effacing 
the residual micro metastases limits ability to cure many cancers 
in standard therapies. Fluorescence microendoscopy was used to 
monitor immunoconjugate activation and micrometastatic disease. 
Tumor-targeted, activatable photoimmunotherapy’ (taPIT) has been 
demonstrated in a mouse model of peritoneal carcinomatosis.
CONCLUSION
In conclusion, outstanding, rapid progress of great scope has put NIR 
dyes in the center of attention. NIR dyes’ tunable chemical, photo-
chemical, and photophysical properties with their minimal toxicity 
make these dyes powerful tools not only for NIR imaging in divergent 
fields but also for PDT of various diseases. Although NIR dyes’ utility is 
widely accepted, the only clinically approved (FDA approved) mate-
rial is indocyanine green (ICG). ICG has a quantum yield of only 0.01 
in aqueous solution, which is very poor compared to other NIR dyes. 
Moreover, there have been reports of poor stability, rapid clearance 
from the liver, and cytotoxicity. It is very clear that there is a great 
need for new NIR dyes having high fluorescence quantum yield, im-
proved molar absorptivity, and low cytotoxicity that could be used in 
clinics and/or in pre-clinical studies.
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